<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003958.pub2" GROUP_ID="NEONATAL" ID="980602072012165432" MERGED_FROM="" MODIFIED="2008-10-30 20:35:16 +0100" MODIFIED_BY="Diane Haughton" NOTES="&lt;p&gt;Exported from Review Manager 4.2.2&lt;br&gt;Exported from Review Manager 4.2&lt;/p&gt;&lt;p&gt;Old title: Adrenaline for prevention of morbidity and mortality in preterm infants with cardiovascular compromise.&lt;/p&gt;&lt;p&gt;Do not remove&lt;/p&gt;&lt;p&gt;CL 1/04 (review)&lt;/p&gt;&lt;p&gt;Synopsis added Jan 15/04&lt;/p&gt;&lt;p&gt;Sent to Loni Dec 6/06&lt;/p&gt;" NOTES_MODIFIED="2008-10-15 13:59:39 -0400" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="MP1" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2008-10-30 20:35:16 +0100" MODIFIED_BY="Diane Haughton">
<TITLE>Adrenaline for prevention of morbidity and mortality in preterm infants with cardiovascular compromise</TITLE>
<CONTACT MODIFIED="2008-10-30 20:35:16 +0100" MODIFIED_BY="Diane Haughton"><PERSON ID="15299" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Mary</FIRST_NAME><LAST_NAME>Paradisis</LAST_NAME><POSITION>Staff Neonatologist</POSITION><EMAIL_1>mparadisis@med.usyd.edu.au</EMAIL_1><ADDRESS><DEPARTMENT>Pediatrics and Child Health</DEPARTMENT><ORGANISATION>Royal North Shore Hospital, The University of Sydney</ORGANISATION><CITY>Sydney</CITY><ZIP>2006</ZIP><REGION>NSW</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>61 2 99267509</PHONE_1><PHONE_2>61 2 99266155</PHONE_2></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-10-30 20:35:16 +0100" MODIFIED_BY="Diane Haughton"><PERSON ID="15299" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Mary</FIRST_NAME><LAST_NAME>Paradisis</LAST_NAME><POSITION>Staff Neonatologist</POSITION><EMAIL_1>mparadisis@med.usyd.edu.au</EMAIL_1><ADDRESS><DEPARTMENT>Pediatrics and Child Health</DEPARTMENT><ORGANISATION>Royal North Shore Hospital, The University of Sydney</ORGANISATION><CITY>Sydney</CITY><ZIP>2006</ZIP><REGION>NSW</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>61 2 99267509</PHONE_1><PHONE_2>61 2 99266155</PHONE_2></ADDRESS></PERSON><PERSON ID="17768" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>David</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Osborn</LAST_NAME><POSITION>Clinical Associate Professor</POSITION><EMAIL_1>david.osborn@email.cs.nsw.gov.au</EMAIL_1><ADDRESS><DEPARTMENT>RPA Newborn Care</DEPARTMENT><ORGANISATION>Royal Prince Alfred Hospital</ORGANISATION><ADDRESS_1>Missenden Road</ADDRESS_1><CITY>Camperdown</CITY><ZIP>2050</ZIP><REGION>New South Wales</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 2 95158363 </PHONE_1><FAX_1>+61 2 95504375 </FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-10-30 20:35:16 +0100" MODIFIED_BY="Diane Haughton">
<UP_TO_DATE>
<DATE DAY="12" MONTH="9" YEAR="2003"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="12" MONTH="9" YEAR="2003"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="30" MONTH="5" YEAR="2005"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2004"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2004"/>
</DATES>
<WHATS_NEW>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="15" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="12" MONTH="9" YEAR="2003"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>RPA Newborn Care, Royal Prince Alfred Hospital, Sydney</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Centre for Perinatal Health Services Research, University of Sydney</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-10-15 13:49:36 -0400" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-10-15 13:49:19 -0400" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-10-15 13:49:16 -0400" MODIFIED_BY="[Empty name]">Adrenaline for prevention of morbidity and mortality in preterm infants with cardiovascular compromise</TITLE>
<SUMMARY_BODY MODIFIED="2008-10-15 13:49:19 -0400" MODIFIED_BY="[Empty name]">
<P>Not enough evidence from trials on the use of adrenaline (epinephrine) for preterm babies with poor heart rates and circulation. Sustained poor blood flow in preterm babies can lead to complications, including impaired development. Inotrope drugs, particularly dopamine and dobutamine, are commonly used to increase heart rate and blood pressure in preterm babies with poor circulation. Adrenaline (epinephrine) is another inotrope drug that can be used. The review found that there is not enough evidence from trials to show the effects of adrenaline on preterm babies with poor circulation, and more research is needed.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Inotropes are widely used in preterm infants to treat cardiovascular compromise, which may result from early adaptive problems of the transitional circulation, perinatal asphyxia or sepsis. Sustained hypotension and poor organ blood flow are associated with brain injury including peri/intraventricular haemorrhage and subsequent poor neurodevelopmental outcomes. Adrenaline (epinephrine) infusions are used in preterm infants with clinical cardiovascular compromise. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To determine the effectiveness and safety of adrenaline compared to no treatment or other inotropes in reducing mortality and morbidity in preterm infants with cardiovascular compromise.<BR/> </P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>Randomised controlled trials were identified by searching MEDLINE (1966-August 2003), The Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library, Issue 3, 2003) and EMBASE (1980 - 2003), supplemented with searches of reference lists of published trials and abstracts of conference proceedings.<BR/> </P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised controlled trials of preterm newborn infants that compared adrenaline to no treatment or other inotropic agents (including dopamine, dobutamine, noradrenaline or isoprenaline).</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Data were extracted and analysed independently by two reviewers. Treatment effects on the following outcomes were to be determined: mortality in the newborn period, long term neurodevelopmental outcomes, radiological evidence of brain injury, short term haemodynamic changes, adverse drug effects and short term neonatal outcomes. Study authors were contacted for additional information. Studies were analysed for methodological quality using the criteria of the Cochrane Neonatal Review Group.<BR/> </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>One ongoing study (Pellicer 2003) was identified. One study comparing adrenaline with dopamine infusion was included but was published in abstract form only (Phillipos 1996). It enrolled hypotensive, predominately preterm infants in the first 24 hours. Only infants &gt;1750g are included in this review (report for infants &lt;=1750g appears incomplete). The study was reported as being randomised and double blinded, but methods were not reported. Both adrenaline and dopamine significantly increased heart rate and mean BP, with no statistically significant effect on left or right ventricular outputs. No other clinical outcomes were reported. No studies were identified that compared adrenaline to other inotropes, placebo or no treatment.<BR/> </P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>There are insufficient data on the use of adrenaline infusions in preterm infants with cardiovascular compromise to make recommendations for practice. There is a need for larger trials to determine whether adrenaline is effective in reducing morbidity and mortality in preterm infants with cardiovascular compromise. </P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-10-15 13:49:36 -0400" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2008-10-15 13:49:35 -0400" MODIFIED_BY="[Empty name]">
<P>In the preterm infant cardiovascular compromise may be the result of early adaptive problems of the transitional circulation including high systemic vascular resistance, shunts across the adapting heart and an immature myocardium (<LINK REF="REF-Gill-1993" TYPE="REFERENCE">Gill 1993</LINK>; <LINK REF="REF-Seri-1995" TYPE="REFERENCE">Seri 1995</LINK>; <LINK REF="REF-Kluckow-2000" TYPE="REFERENCE">Kluckow 2000</LINK>; <LINK REF="REF-Osborn-2002a" TYPE="REFERENCE">Osborn 2002a</LINK>). In addition, sepsis, asphyxia or uncommonly hypovolaemia may also produce cardiovascular compromise (<LINK REF="REF-Gill-1993" TYPE="REFERENCE">Gill 1993</LINK>; <LINK REF="REF-Seri-1995" TYPE="REFERENCE">Seri 1995</LINK>). Subsequent poor organ blood flow is associated with injury including peri/intraventricular haemorrhage (P/IVH) (<LINK REF="REF-Kluckow-2000" TYPE="REFERENCE">Kluckow 2000</LINK>; <LINK REF="REF-Meek-1999" TYPE="REFERENCE">Meek 1999</LINK>; <LINK REF="REF-Osborn-2002b" TYPE="REFERENCE">Osborn 2002b</LINK>) and possibly periventricular leucomalacia (PVL), necrotising enterocolitis (<LINK REF="REF-Osborn-2002b" TYPE="REFERENCE">Osborn 2002b</LINK>) and renal impairment (<LINK REF="REF-Kluckow-2001" TYPE="REFERENCE">Kluckow 2001</LINK>). Clinical features used to detect cardiovascular compromise include hypotension, increased capillary filling time, metabolic acidosis and evidence of impaired organ function (e.g. low urine output). Cardiac output or organ blood flow may be measured directly using Doppler ultrasound or other techniques. Whereas sustained hypotension has been associated with P/IVH (<LINK REF="REF-Bada-1990" TYPE="REFERENCE">Bada 1990</LINK>; <LINK REF="REF-Miall_x002d_Allen-1987" TYPE="REFERENCE">Miall-Allen 1987</LINK>) and poor neurodevelopmental outcome (<LINK REF="REF-Goldstein-1995" TYPE="REFERENCE">Goldstein 1995</LINK>; <LINK REF="REF-Murphy-1997" TYPE="REFERENCE">Murphy 1997</LINK>), studies using Doppler ultrasound have demonstrated that hypotension is imperfectly correlated with systemic blood flow measured using Doppler (<LINK REF="REF-Kluckow-1996" TYPE="REFERENCE">Kluckow 1996</LINK>; <LINK REF="REF-Kluckow-2000" TYPE="REFERENCE">Kluckow 2000</LINK>). Low upper body blood flow has been associated with increased mortality (<LINK REF="REF-Osborn-2003" TYPE="REFERENCE">Osborn 2003</LINK>) and late P/IVH (<LINK REF="REF-Kluckow-2000" TYPE="REFERENCE">Kluckow 2000</LINK>; <LINK REF="REF-Osborn-2003" TYPE="REFERENCE">Osborn 2003</LINK>). The association with subsequent poor neurodevelopmental outcome is reported to be stronger for reduced blood flow than for blood pressure (<LINK REF="REF-Hunt-2001" TYPE="REFERENCE">Hunt 2001</LINK>).</P>
<P>Treatment options for preterm infants with cardiovascular compromise include inotropes, volume expansion and corticosteroids. Inotropes that have the potential for use in preterm infants include adrenaline, dobutamine, dopamine, isoprenaline and noradrenaline. These inotropes have varying pharmacological effects which include increased myocardial contractility and heart rate (via beta receptors), and reduced (via beta receptors) or increased (via alpha receptors) vascular resistance. The mechanism of action is often dose dependent and also depends on which receptors are stimulated.</P>
<P>Adrenaline infusions are most frequently used in neonates for the treatment of hypotension and pulmonary hypertension (<LINK REF="REF-Perkin-1982" TYPE="REFERENCE">Perkin 1982</LINK>; <LINK REF="REF-Zaritsky-1984" TYPE="REFERENCE">Zaritsky 1984</LINK>). Adrenaline has both alpha and beta receptor agonist effects (<LINK REF="REF-Seri-1995" TYPE="REFERENCE">Seri 1995</LINK>; <LINK REF="REF-Zaritsky-1984" TYPE="REFERENCE">Zaritsky 1984</LINK>). At low dose it is a potent inotrope, chronotrope and systemic and pulmonary vasodilator. At higher doses it has differential effects on the systemic and pulmonary circulations, increasing systemic pressure more than pulmonary pressure (<LINK REF="REF-Barrington-1993" TYPE="REFERENCE">Barrington 1993</LINK>; <LINK REF="REF-Barrington-1995" TYPE="REFERENCE">Barrington 1995</LINK>). Animal studies have demonstrated improvement in cardiac output (<LINK REF="REF-Barrington-1993" TYPE="REFERENCE">Barrington 1993</LINK>; <LINK REF="REF-Cheung-1997" TYPE="REFERENCE">Cheung 1997</LINK>), myocardial perfusion (<LINK REF="REF-Barrington-1995" TYPE="REFERENCE">Barrington 1995</LINK>) and increased mesenteric vascular resistance (<LINK REF="REF-Cheung-1997" TYPE="REFERENCE">Cheung 1997</LINK>). Reported adverse effects of adrenaline infusion in the neonate include increases in peripheral vascular resistance leading to decreased cardiac output and tissue perfusion, hypertension, tachycardia and severe tissue necrosis with extravasation of the infusate (<LINK REF="REF-Perkin-1982" TYPE="REFERENCE">Perkin 1982</LINK>; <LINK REF="REF-Seri-2001" TYPE="REFERENCE">Seri 2001</LINK>). There is a paucity of published studies regarding the circulatory effects of adrenaline infusion in the neonate (<LINK REF="REF-Seri-1998a" TYPE="REFERENCE">Seri 1998a</LINK>; <LINK REF="REF-Campbell-1998" TYPE="REFERENCE">Campbell 1998</LINK>) and there is no systematic review of the use of adrenaline in preterm infants with cardiovascular compromise.</P>
<P>Dopamine has been used extensively in neonates for treatment of hypotension and also has dose dependent actions. Low infusion rates (0.5 to 5 microgram/kg/min) are used to improve renal function. Medium ranges (6 to 10 microgram/kg/min) are used for treatment of heart failure. With doses up to 10 microgram/kg/min there is an increase in blood pressure (<LINK REF="REF-Osborn-2002b" TYPE="REFERENCE">Osborn 2002b</LINK>; <LINK REF="REF-Padbury-1987" TYPE="REFERENCE">Padbury 1987</LINK>) and possibly cardiac output (<LINK REF="REF-Lundstrom-2000" TYPE="REFERENCE">Lundstrom 2000</LINK>; <LINK REF="REF-Osborn-2002b" TYPE="REFERENCE">Osborn 2002b</LINK>; <LINK REF="REF-Padbury-1987" TYPE="REFERENCE">Padbury 1987</LINK>). However, there is concern that higher doses may only increase blood pressure with no improvement in cardiac function or output (<LINK REF="REF-Osborn-2002b" TYPE="REFERENCE">Osborn 2002b</LINK>; <LINK REF="REF-Roze-1993" TYPE="REFERENCE">Roze 1993</LINK>). The usual justification of using dopamine in hypotensive preterm infants is to increase cerebral perfusion and avoid ischaemic injury. However, there is no evidence yet that cerebral blood flow is increased by the use of dopamine (<LINK REF="REF-Lundstrom-2000" TYPE="REFERENCE">Lundstrom 2000</LINK>; <LINK REF="REF-Seri-1998b" TYPE="REFERENCE">Seri 1998b</LINK>; <LINK REF="REF-Barrington-1995" TYPE="REFERENCE">Barrington 1995</LINK>; <LINK REF="REF-Osborn-2002b" TYPE="REFERENCE">Osborn 2002b</LINK>). In the neonate, dopamine has no significant effect on mesenteric blood flow (<LINK REF="REF-Seri-1998b" TYPE="REFERENCE">Seri 1998b</LINK>; <LINK REF="REF-Cheung-1997" TYPE="REFERENCE">Cheung 1997</LINK>) or coronary blood flow (<LINK REF="REF-Barrington-1995" TYPE="REFERENCE">Barrington 1995</LINK>). Reported adverse effects of dopamine in the neonate include severe vasoconstriction, local tissue necrosis if extravasation occurs, tachyarrhythmia (<LINK REF="REF-Seri-1995" TYPE="REFERENCE">Seri 1995</LINK>) and hepatic injury after inappropriately placed umbilical venous catheter (<LINK REF="REF-Venkataraman-1984" TYPE="REFERENCE">Venkataraman 1984</LINK>).</P>
<P>Dobutamine, an inotrope with predominantly beta receptor effects, has been used in asphyxiated hypotensive preterm infants with myocardial dysfunction (<LINK REF="REF-Perkin-1982" TYPE="REFERENCE">Perkin 1982</LINK>; <LINK REF="REF-Seri-2001" TYPE="REFERENCE">Seri 2001</LINK>), and has been compared to dopamine in several randomised trials in preterm infants with hypotension (<LINK REF="REF-Subhedar-2002" TYPE="REFERENCE">Subhedar 2002</LINK>) or low blood flow (<LINK REF="REF-Osborn-2002b" TYPE="REFERENCE">Osborn 2002b</LINK>). The dose range used to increase cardiac output has been up to 20 micrograms/kg/min (<LINK REF="REF-Osborn-2002b" TYPE="REFERENCE">Osborn 2002b</LINK>). Potential adverse effects are similar to the other inotropes and include tachyarrhythmia and hypertension (<LINK REF="REF-Seri-2001" TYPE="REFERENCE">Seri 2001</LINK>), although hypertension is unusual (<LINK REF="REF-Osborn-2002b" TYPE="REFERENCE">Osborn 2002b</LINK>). The effects of dopamine versus dobutamine have been examined in a systematic review (<LINK REF="REF-Subhedar-2002" TYPE="REFERENCE">Subhedar 2002</LINK>). Dopamine was more effective than dobutamine for treatment of systemic hypotension in the short term. However, there was insufficient evidence concerning long term benefits and safety to give firm recommendations on the choice of drug to treat neonatal hypotension. Noradrenaline has both alpha and beta activity, producing greater increases in vascular resistance than the other inotropes (<LINK REF="REF-Zaritsky-1984" TYPE="REFERENCE">Zaritsky 1984</LINK>). The adverse side effects are similar to adrenaline. There is a paucity of studies with noradrenaline in the preterm population (<LINK REF="REF-Derleth-1997" TYPE="REFERENCE">Derleth 1997</LINK>). Isoprenaline is a synthetic catecholamine with almost purely beta effects (<LINK REF="REF-Zaritsky-1984" TYPE="REFERENCE">Zaritsky 1984</LINK>) with an important adverse effect being tachyarrhythmia.</P>
<P>This review will examine the evidence for the use of adrenaline compared to no treatment or other inotropes for the treatment of preterm infants with cardiovascular compromise. As preterm infants may have different underlying causes of cardiovascular compromise or have different clinical indications for inotrope treatment, subgroup analysis will examine the evidence for use of adrenaline depending on aetiology of compromise or clinical indication for inotrope. This review should be viewed in the context of other Cochrane reviews of cardiovascular interventions in preterm infants including those examining dopamine and dobutamine for hypotension (<LINK REF="REF-Subhedar-2002" TYPE="REFERENCE">Subhedar 2002</LINK>), corticosteroids for hypotension (<LINK REF="REF-Whitelaw-2002" TYPE="REFERENCE">Whitelaw 2002</LINK>), and early volume expansion (<LINK REF="REF-Osborn-2002c" TYPE="REFERENCE">Osborn 2002c</LINK>; <LINK REF="REF-Osborn-2002d" TYPE="REFERENCE">Osborn 2002d</LINK>).</P>
</BACKGROUND>
<OBJECTIVES>
<P>The aim of this review was to examine the evidence for the effectiveness and safety of adrenaline compared to no treatment or other inotropes in reducing mortality and morbidity in preterm infants with cardiovascular compromise. <BR/>Subgroup analysis was prespecified according to:<BR/>
</P>
<UL>
<LI>aetiology of cardiovascular compromise </LI>
<LI>indicator used to define cardiovascular compromise (clinical or echocardiography)</LI>
<LI>dose range used for each inotrope </LI>
</UL>
</OBJECTIVES>
<METHODS MODIFIED="2008-10-15 13:49:35 -0400" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>Randomised controlled trials that compared adrenaline to no treatment or other inotropic agents (including dopamine, dobutamine, noradrenaline or isoprenaline).<BR/> </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Preterm infants &lt;37 weeks gestation with evidence of cardiovascular compromise. Cardiovascular compromise was defined:<BR/>
</P>
<UL>
<LI>Clinically: using indicators of poor perfusion (hypotension: as defined by the individual study investigators, thus the criteria for hypotension may vary between studies), metabolic acidosis, increased capillary refill time or evidence of organ dysfunction (e.g. low urine output).</LI>
<LI>Using direct measures of cardiac output or organ perfusion (e.g. echocardiography or other techniques)</LI>
</UL>
<P> </P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Adrenaline infusion at any dose compared to no treatment (including placebo) or infusion of other inotrope (including dopamine, dobutamine, noradrenaline or isoprenaline)</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>Primary:<BR/>1. Mortality in neonatal period (&lt;28 days) or to discharge from hospital<BR/>2. Long term neurodevelopmental outcome: cerebral palsy and standardised assessment of developmental delay or sensorineural impairment <BR/>3. Periventricular or intraventricular haemorrhage (any grade of severity)<BR/>4. Periventricular leukomalacia<BR/> <BR/>Secondary<BR/>1. Short term haemodynamic changes:<BR/>
</P>
<UL>
<LI>failure to correct systemic hypotension </LI>
<LI>failure to correct low systemic or organ blood flow </LI>
<LI>mean increase in cardiac output or systemic blood flow (defined by Doppler echocardiography)</LI>
<LI>mean increase in blood pressure (hypotension, as defined by individual studies)</LI>
</UL>
<P>
<BR/>2. Drug side effects: <BR/>
</P>
<UL>
<LI>tachyarrhythmias</LI>
<LI>extravasation of infusate</LI>
<LI>hepatic injury</LI>
</UL>
<P>
<BR/>3. Other short term neonatal outcomes:<BR/>
</P>
<UL>
<LI>patent ductus arteriosus</LI>
<LI>gastrointestinal complications (perforation, necrotising enterocolitis)</LI>
<LI>chronic lung disease (respiratory support at 28 days age or &gt;36 weeks postmenstrual age)</LI>
<LI>duration of ventilation and respiratory support</LI>
<LI>duration of hospital stay</LI>
<LI>renal complications (oliguria defined as urine output &lt; 0.5 ml/kg/hr for &gt; 24 hours or creatinine &gt; 120 umol/l)</LI>
</UL>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>See: Cochrane Neonatal Group Search Strategy</P>
<P>The standard search method of the Cochrane Neonatal Group as described in the Cochrane Library was used. The following electronic databases were searched: MEDLINE (1966 - August 2003), The Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library, Issue 3, 2003) and EMBASE (1980 - August 2003). In addition, recent abstracts, conferences and cited references from retrieved articles were hand searched. Unpublished studies were sought by hand searching the conference proceedings of the Society for Pediatric Research (1998-2003). Search strategies were developed using the following keywords/index terms: 'infant, pre term', 'hypotension', 'adrenaline or epinephrine', 'dopamine', 'dobutamine', 'isoproterenol', 'inotrope', 'sepsis', 'asphyxia' . Searches were limited to randomised controlled trials. There was no language restriction. </P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-10-15 13:49:35 -0400" MODIFIED_BY="[Empty name]">
<P>The standard search method of the Cochrane Neonatal Review Group (CNRG) as described in the Cochrane Collaboration Handbook was used to conduct this systematic review.</P>
<P>The pre-specified inclusion criteria regarding gestational age were adjusted after review of the studies. <LINK REF="STD-Phillipos-1996" TYPE="STUDY">Phillipos 1996</LINK> included infants that were both term and preterm. It is not stated how many infants were term or preterm; however, as the mean gestational age was 36 weeks, a decision was made to include this study.</P>
<P>The methodological quality of studies was assessed as recommended by the CNRG. Two reviewers independently assessed and selected the studies to be included in the review. Studies were assessed for methodological quality using the following criteria: allocation concealment, blinding of randomisation, completeness of follow up and blinding of the outcome measure. Data were extracted independently by the reviewers. Additional information was requested from the study authors of the studies that were assessed to be eligible. Authors were contacted by e-mail for additional information regarding individual patient data for haemodynamic measures and any other outcomes. The author of one study (<LINK REF="STD-Phillipos-1996" TYPE="STUDY">Phillipos 1996</LINK>) provided a copy of conference proceedings but has not yet provided any further information. The authors of an ongoing study (<LINK REF="STD-Pellicer-2003" TYPE="STUDY">Pellicer 2003</LINK>) have provided information regarding the progress of the study to date.</P>
<P>Statistical analysis: When available, data will be analysed using the standard methods of the CNRG. Treatment effects will be analysed using relative risk (RR), risk difference (RD) and number needed to treat (NNT) for categorical outcomes, and mean difference (MD) and weighted mean difference (WMD) for continuous outcomes, with 95% confidence intervals where appropriate. Heterogeneity between studies will be examined. Meta-analysis will be performed for studies where treatments are used for similar patients and similar dosage schedules. A fixed effect model will be used for the meta analysis unless significant heterogeneity exists between studies, in which case the cause of the heterogeneity will be explored and if appropriate, a random effects model used. Sensitivity analysis will be performed including only studies of good methodology (adequate randomisation and allocation concealment and &lt;10% post randomisation losses).</P>
<P>Subgroup analysis were to be performed according to trials that enrolled infants on the basis of :<BR/>1. Aetiology of cardiovascular compromise<BR/>
</P>
<UL>
<LI>transitional circulation (defined as early cardiovascular compromise in preterm infants without obvious cause such as sepsis or asphyxia)</LI>
<LI>sepsis (proven and suspected)</LI>
<LI>perinatal asphyxia: as evidenced by cord pH &lt; 7.0 and/or cord base excess &lt; -16 mEq/L and/or 5 minute Apgar score &lt; 6</LI>
</UL>
<P>
<BR/>2. Indicator used to define poor cardiovascular function<BR/>
</P>
<UL>
<LI>clinical e.g. hypotension; or</LI>
<LI>echocardiography e.g. low systemic or organ blood flow</LI>
</UL>
<P>
<BR/>3. Dose range of inotrope used:<BR/>
</P>
<UL>
<LI>Adrenaline (up to 0.16 microgram/kg/min)</LI>
<LI>Dopamine (0 - 5, 6 -10 and &gt;10 microgram/kg/min),</LI>
</UL>
<P>
<BR/>4. Age at initiation of therapy (early &lt; 72 h v late &gt; 72h)
<BR/>

<I>
<BR/>
</I>
</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-10-15 13:49:36 -0400" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2008-10-15 13:49:36 -0400" MODIFIED_BY="[Empty name]">
<P>Two studies were identified that compared adrenaline with dopamine in preterm infants with hypotension. One study (<LINK REF="STD-Phillipos-1996" TYPE="STUDY">Phillipos 1996</LINK>) published in abstract form has been included and one study (<LINK REF="STD-Pellicer-2003" TYPE="STUDY">Pellicer 2003</LINK>) is ongoing . No studies were identified that enrolled infants with low blood flow or compared adrenaline to any other inotrope, a placebo or no treatment.</P>
<P>Infants: <LINK REF="STD-Phillipos-1996" TYPE="STUDY">Phillipos 1996</LINK> enrolled hypotensive newborn infants &lt;24 hours age with a mean BP one SD below mean for weight (using data from <LINK REF="REF-Versmold-1981" TYPE="REFERENCE">Versmold 1981</LINK>) and indwelling arterial line. Infants were stratified into three groups of 20 infants: 750-1250g, 1251-1750g and &gt;1750g. Infants with congenital heart disease were excluded. For infants &gt;1750g, the dopamine group had a mean gestation of 34 (range 30-34) weeks and birth weight 2471g; the adrenaline group had a mean gestation 36 (range 34-41) weeks and mean birthweight 2642g. Seven infants in each group had a patent ductus arteriosus. For infants &lt;=1750g, only 16 of the anticipated 40 infants are reported. Clarification as to whether this is an ongoing or completed study has been sought from the author. This review will only report outcomes for infants &gt;1750g. Infants &lt;1750g were not included in the current review as we are awaiting clarification from the authors regarding the completion status of the study. When these data become available, it is intended that they be included in a future update of this review.</P>
<P>Interventions: <LINK REF="STD-Phillipos-1996" TYPE="STUDY">Phillipos 1996</LINK> allocated infants to dopamine or adrenaline. Dopamine was started at 5 and then increased to 10, 15 and 20 micrograms/kg/min every 20 minutes, and adrenaline was started at 0.125 and increased 0.25, 0.375 and 0.5 micrograms/kg/min every 20 minutes till desired mean BP was achieved for at least one hour. If the desired BP was not achieved, the other drug was added.</P>
<P>Measurement: <LINK REF="STD-Phillipos-1996" TYPE="STUDY">Phillipos 1996</LINK> used invasive BP monitoring of all infants and used 2-D echocardiography to determine left and right ventricular output, left and right stroke volume index, and mean pulmonary artery pressure.<BR/>No other clinical outcomes were reported.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-10-15 13:49:36 -0400" MODIFIED_BY="[Empty name]">
<P>The overall methodological quality of the included trial is unclear. <LINK REF="STD-Phillipos-1996" TYPE="STUDY">Phillipos 1996</LINK> reported the study to be randomised and double blinded. However, the method of randomisation and blinding were not reported. Allocation concealment is unclear. For infants &gt;1750g, in an initial report <LINK REF="STD-Phillipos-1996" TYPE="STUDY">Phillipos 1996</LINK> reported data for heart rate, mean BP and left and right ventricular output for all 20 infants, but did not report standard deviations. In a second report, <LINK REF="STD-Phillipos-1996" TYPE="STUDY">Phillipos 1996</LINK> excluded 2 (10%) infants but reported both means and standard errors. For infants &lt;=1750g, as only 16 of the anticipated 40 infants have been reported, these infants are not included in this review. Clarification has been sought from the author. 
<BR/>

</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-10-15 13:49:35 -0400" MODIFIED_BY="[Empty name]">
<P>One study (<LINK REF="STD-Phillipos-1996" TYPE="STUDY">Phillipos 1996</LINK>) enrolling a total of 20 infants &gt;1750g met eligibility criteria and was included in this systematic review. No outcome data were able to be entered into the analysis tables, so all treatment effects are reported in text. 
<BR/>

<BR/>
<U>Primary clinical outcomes<BR/>
</U>Effects on mortality, neurodevelopmental outcome, periventricular or intraventricular haemorrhage (any grade of severity), and periventricular leukomalacia were not reported.</P>
<P>
<U>Secondary outcomes: Short term haemodynamic changes</U>
<BR/>Failure to correct systemic hypotension or failure to correct low systemic or organ blood flow was not reported. For infants &gt;1750g, <LINK REF="STD-Phillipos-1996" TYPE="STUDY">Phillipos 1996</LINK> reported a significant increase in mean heart rate and mean BP at the highest dose reached, and at the study endpoint, for both adrenaline and dopamine. The significance of the difference between the two inotropes was not reported. Neither inotrope produced a statistically significant change in left or right ventricular outputs. Dopamine produced a significant fall in left ventricular stroke volume compared to baseline. Whether this was statistically different to the effect of adrenaline was not reported.<BR/>

<BR/>

<U>Secondary outcomes: Drug side effects </U>
<BR/>Tachyarrhythmias, extravasation of infusate and hepatic injury were not reported.</P>
<P>
<U>Secondary outcomes: Short term neonatal outcomes</U>
<BR/>Patent ductus arteriosus, gastrointestinal complications (perforation, necrotising enterocolitis), chronic lung disease, duration of ventilation and respiratory support, duration of hospital stay and renal complications not reported.</P>
<P>
<U>Subgroup analyses</U>
<BR/>The available trial enrolled predominately preterm infants with hypotension. There is inadequate information in the reported abstracts to determine the aetiology of the cardiovascular compromise although as infants were enrolled in the first day of life it is likely a substantial number had problems with the transitional circulation. The dose ranges used for both adrenaline and dopamine incorporated all prespecified subgroup analyses. No sensitivity analysis was performed as the methodological quality of the included study is unclear.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-10-15 13:49:36 -0400" MODIFIED_BY="[Empty name]">
<P>This review found evidence from one small randomised study (<LINK REF="STD-Phillipos-1996" TYPE="STUDY">Phillipos 1996</LINK>), reporting outcomes in 20 hypotensive infants &gt;1750g in the first 24 hours after birth, that both dopamine and adrenaline increased heart rate and mean blood pressure but did not have a statistically significant effect on left or right ventricular outputs. Outcomes from this trial for infants born &lt;=1750g were excluded from this review as it is unclear whether the reported infants represent a preliminary report of an incomplete study or a study that was stopped early. The available study was of unclear methodological quality as it has been published in abstract form only and methods of randomisation, allocation concealment and blinding were not reported. The study was reported as being randomised and double blinded. No study reported any other clinically important outcomes including mortality and neurodevelopmental outcome. No study enrolled infants with low systemic or organ blood flow or reported incidence of low blood flow.</P>
<P>The limitations of this review include the lack of published reports including methodology and data, and the small numbers of infants enrolled in the included trial. Publication of existing data is important.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>There are insufficient data on the use of adrenaline infusions in preterm infants with cardiovascular compromise to make recommendations for practice. </P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>There is a need for larger trials to determine whether adrenaline is effective at reducing morbidity and mortality in preterm infants with cardiovascular compromise. Trials should enrol infants with evidence of cardiovascular compromise, measure the effects of inotrope infusions on systemic and organ blood flow, and report clinically important outcomes including mortality and neurodevelopmental achievements. </P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS/>
<CONFLICT_OF_INTEREST>
<P>Both the authors are investigators in trials of cardiovascular interventions in preterm infants. </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS/>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-10-15 13:59:39 -0400" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2008-10-15 13:51:24 -0400" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2008-10-15 13:51:24 -0400" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Phillipos-1996" MODIFIED="2008-10-15 13:51:24 -0400" MODIFIED_BY="[Empty name]" NAME="Phillipos 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-10-15 13:50:47 -0400" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Phillipos EZ, Barrington KJ, Robertson MA</AU>
<TI>Dopamine versus epinephrine for inotropic support in the neonate: A randomized double blinded controlled trial</TI>
<SO>Pediatric Research</SO>
<YR>1996</YR>
<VL>39</VL>
<PG>238A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-10-15 13:50:56 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Phillipos EZ, Barrington KJ, Robertson MA</AU>
<TI>The effects of dopamine vs epinephrine on the pulmonary circulation in the sick newborn: A randomized double blinded controlled trial</TI>
<SO>Pediatric Research</SO>
<YR>1996</YR>
<VL>39</VL>
<PG>238A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Phillipos EZ, Robertson MA . A randomized blinded trial of dopamine versus epinephrine for inotropic support in the sick newborn. Proceedings of 2nd World Congress of PCCS&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Phillipos EZ, Robertson MA</AU>
<TI>A randomized blinded trial of dopamine versus epinephrine for inotropic support in the sick newborn</TI>
<SO>Proceedings of the 2nd World Congress of PCCS</SO>
<YR>1997</YR>
<PG>897-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-10-15 13:51:08 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Phillipos EZ, Robertson MA. A randomized double blinded controlled trial of dopamine vs epinephrine for inotropic support in premature infants &amp;lt;1750 grams. Pediatr Res 2000;47:425A&lt;/p&gt;" NOTES_MODIFIED="2008-10-15 13:51:08 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Phillipos EZ, Robertson MA</AU>
<TI>A randomized double blinded controlled trial of dopamine vs epinephrine for inotropic support in premature infants &lt;1750 grams</TI>
<SO>Pediatric Research</SO>
<YR>2000</YR>
<VL>47</VL>
<PG>425A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-10-15 13:51:24 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Phillipos EZ, Robertson MA .A randomized double blinded controlled trial of dopamine vs epinephrine on pulmonary artery pressure in premature infants &amp;lt; 1750 grams Pediatr Res 2000 47, 425A&lt;/p&gt;" NOTES_MODIFIED="2008-10-15 13:51:24 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Phillipos EZ, Robertson MA</AU>
<TI>A randomized double blinded controlled trial of dopamine vs epinephrine on pulmonary artery pressure in premature infants &lt; 1750 grams</TI>
<SO>Pediatric Research</SO>
<YR>2000</YR>
<VL>47</VL>
<PG>425A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES/>
<AWAITING_STUDIES/>
<ONGOING_STUDIES>
<STUDY DATA_SOURCE="MIX" ID="STD-Pellicer-2003" NAME="Pellicer 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Preliminary report as abstract.&lt;/p&gt;" PRIMARY="NO" TYPE="OTHER">
<AU>Pellicer A, Valverde E, Elorza MD, Madero R, Gaya F, Quero J, Cababnas F</AU>
<TI>Randomized blinded controlled trial on the effects on brain hemodynamics of dopamine v epinephrine for inotropic support in preterm infants</TI>
<SO>Pediatric Academic Societies Annual Meeting</SO>
<YR>2003</YR>
<PG>2364A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-10-15 13:59:39 -0400" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-10-15 13:59:39 -0400" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Bada-1990" MODIFIED="2008-10-15 13:51:54 -0400" MODIFIED_BY="[Empty name]" NAME="Bada 1990" TYPE="JOURNAL_ARTICLE">
<AU>Bada HS, Korones SB, Perry EH, Arheart KL, Ray JD, Pourcyrous M, Magill HL, Runyan W 3rd, Somes GW, Clark FC et al</AU>
<TI>Mean arterial blood pressure changes in premature infants and those at risk for intraventricular hemorrhage</TI>
<SO>Journal of Pediatrics</SO>
<YR>1990</YR>
<VL>117</VL>
<PG>607-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barrington-1993" MODIFIED="2008-10-15 13:52:12 -0400" MODIFIED_BY="[Empty name]" NAME="Barrington 1993" TYPE="JOURNAL_ARTICLE">
<AU>Barrington K, Chan W</AU>
<TI>The circulatory effects of epinephrine infusion in the anesthetized piglet</TI>
<SO>Pediatric Research</SO>
<YR>1993</YR>
<VL>33</VL>
<PG>190-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barrington-1995" MODIFIED="2008-10-15 13:52:50 -0400" MODIFIED_BY="[Empty name]" NAME="Barrington 1995" TYPE="JOURNAL_ARTICLE">
<AU>Barrington KJ , Finer NN, Chan WKY</AU>
<TI>A blind, randomized comparison of the circulatory effects of dopamine and epinephrine infusions in the newborn piglet during normoxia and hypoxia</TI>
<SO>Critical Care Medicine</SO>
<YR>1995</YR>
<VL>23</VL>
<PG>740-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Campbell-1998" MODIFIED="2008-10-15 13:53:07 -0400" MODIFIED_BY="[Empty name]" NAME="Campbell 1998" TYPE="JOURNAL_ARTICLE">
<AU>Campbell ME, Byrne PJ</AU>
<TI>Outcome after intravenous epinephrine infusion in infants &lt;750g</TI>
<SO>Pediatric Research</SO>
<YR>1998</YR>
<VL>43</VL>
<PG>209A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cheung-1997" MODIFIED="2008-10-15 13:52:34 -0400" MODIFIED_BY="[Empty name]" NAME="Cheung 1997" TYPE="JOURNAL_ARTICLE">
<AU>Cheung PY, Barrington KJ, Pearson RJ, Bigam DL, Finer NN, Van Aerde J</AU>
<TI>Systemic, pulmonary, and mesenteric perfusion and oxygenation effects of dopamine and epinephrine</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>1997</YR>
<VL>155</VL>
<PG>32-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Derleth-1997" MODIFIED="2008-10-15 13:53:17 -0400" MODIFIED_BY="[Empty name]" NAME="Derleth 1997" TYPE="JOURNAL_ARTICLE">
<AU>Derleth DP</AU>
<TI>Clinical experience with norepinephrine infusions in critically ill newborns</TI>
<SO>Pediatric Research</SO>
<YR>1997</YR>
<VL>40</VL>
<PG>145A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gill-1993" MODIFIED="2008-10-15 13:53:30 -0400" MODIFIED_BY="[Empty name]" NAME="Gill 1993" TYPE="JOURNAL_ARTICLE">
<AU>Gill AB, Weindling AM</AU>
<TI>Echocardiographic assessment of cardiac function in shocked very low birthweight infants</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1993</YR>
<VL>68</VL>
<PG>17-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goldstein-1995" NAME="Goldstein 1995" TYPE="JOURNAL_ARTICLE">
<AU>Goldstein RF, Thompson RJ Jr, Oehler JM, Brazy JE</AU>
<TI>Influence of acidosis, hypoxemia and hypotension on neurodevelopmental outcome in very low birth weight infants</TI>
<SO>Pediatrics</SO>
<YR>1995</YR>
<VL>95</VL>
<PG>238-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hunt-2001" MODIFIED="2008-10-15 13:53:39 -0400" MODIFIED_BY="[Empty name]" NAME="Hunt 2001" TYPE="JOURNAL_ARTICLE">
<AU>Hunt RW, Evans N, Rieger I, Kluckow M</AU>
<TI>Low superior vena cava flow in the first 24 hours of life and 3 year neurodevelopmental outcome</TI>
<SO>Pediatric Research</SO>
<YR>2001</YR>
<VL>49</VL>
<PG>336A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kluckow-1996" MODIFIED="2008-10-15 13:53:59 -0400" MODIFIED_BY="[Empty name]" NAME="Kluckow 1996" TYPE="JOURNAL_ARTICLE">
<AU>Kluckow M, Evans N</AU>
<TI>Relationship between blood pressure and cardiac output in preterm infants requiring mechanical ventilation</TI>
<SO>Journal of Pediatrics</SO>
<YR>1996</YR>
<VL>129</VL>
<PG>506-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kluckow-2000" MODIFIED="2008-10-15 13:54:11 -0400" MODIFIED_BY="[Empty name]" NAME="Kluckow 2000" TYPE="JOURNAL_ARTICLE">
<AU>Kluckow M, Evans N</AU>
<TI>Low superior vena cava flow and intraventricular haemorrhage in preterm infants</TI>
<SO>Archives of Disease in Childhood. Fetal and Neonatal Edition</SO>
<YR>2000</YR>
<VL>82</VL>
<PG>F188-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kluckow-2001" NAME="Kluckow 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kluckow M, Evans N</AU>
<TI>Low systemic blood flow in the preterm infant</TI>
<SO>Semin Neonatol</SO>
<YR>2001</YR>
<VL>6</VL>
<PG>75-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lundstrom-2000" MODIFIED="2008-10-15 13:54:28 -0400" MODIFIED_BY="[Empty name]" NAME="Lundstrom 2000" TYPE="JOURNAL_ARTICLE">
<AU>Lundstrom K, Pryds O, Greisen G</AU>
<TI>The haemodynamic effects of dopamine and volume expansion in sick preterm infants</TI>
<SO>Early Human Development</SO>
<YR>2000</YR>
<VL>57</VL>
<PG>157-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Meek-1999" MODIFIED="2008-10-15 13:54:44 -0400" MODIFIED_BY="[Empty name]" NAME="Meek 1999" TYPE="JOURNAL_ARTICLE">
<AU>Meek J, Tyszczuk L, Elwell CE, Wyatt JS</AU>
<TI>Low cerebral blood flow is a risk factor for severe intraventricular haemorrhage</TI>
<SO>Archives of Disease in Childhood. Fetal and Neonatal Edition</SO>
<YR>1999</YR>
<VL>81</VL>
<PG>F15-F18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Miall_x002d_Allen-1987" MODIFIED="2008-10-15 13:54:53 -0400" MODIFIED_BY="[Empty name]" NAME="Miall-Allen 1987" TYPE="JOURNAL_ARTICLE">
<AU>Miall-Allen VM, de Vries LS, Whitelaw AG</AU>
<TI>Mean arterial blood pressure and neonatal cerebral lesions</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1987</YR>
<VL>62</VL>
<PG>1068-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Murphy-1997" NAME="Murphy 1997" TYPE="JOURNAL_ARTICLE">
<AU>Murphy DJ, Hope P, Johnson A</AU>
<TI>Neonatal risk factors for cerebral palsy in very preterm babies: case-control study</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>314</VL>
<PG>404-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Osborn-2002a" MODIFIED="2008-10-15 13:55:06 -0400" MODIFIED_BY="[Empty name]" NAME="Osborn 2002a" TYPE="JOURNAL_ARTICLE">
<AU>Osborn DA, Evans N, Kluckow M</AU>
<TI>Left ventricular contractility and wall stress in very preterm infants in the first day of life</TI>
<SO>Pediatric Research</SO>
<YR>2002</YR>
<VL>51</VL>
<PG>386A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Osborn-2002b" MODIFIED="2008-10-15 13:55:29 -0400" MODIFIED_BY="[Empty name]" NAME="Osborn 2002b" TYPE="JOURNAL_ARTICLE">
<AU>Osborn D, Evans N, Kluckow M</AU>
<TI>Randomised trial of dobutamine versus dopamine in preterm infants with low systemic blood flow</TI>
<SO>Journal of Pediatrics</SO>
<YR>2002</YR>
<VL>140</VL>
<PG>183-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Osborn-2002c" MODIFIED="2008-10-15 13:55:15 -0400" MODIFIED_BY="[Empty name]" NAME="Osborn 2002c" NOTES="&lt;p&gt;Osborn DA, Evans N. Early volume expansion for prevention of morbidity and mortality in very preterm infants (Cochrane &lt;br&gt;Review). In: The Cochrane Library, Issue 3, 2002. Oxford: Update Software.&lt;/p&gt;" NOTES_MODIFIED="2008-10-15 13:55:15 -0400" NOTES_MODIFIED_BY="[Empty name]" TYPE="COCHRANE_REVIEW">
<AU>Osborn DA, Evans N</AU>
<TI>Early volume expansion for prevention of morbidity and mortality in very preterm infants (Cochrane Review)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>3</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Osborn-2002d" MODIFIED="2008-10-15 13:58:32 -0400" MODIFIED_BY="[Empty name]" NAME="Osborn 2002d" NOTES="&lt;p&gt;Osborn DA, Evans N. Early volume expansion versus inotrope for prevention of morbidity and mortality in very preterm &lt;br&gt;infants (Cochrane Review). In: The Cochrane Library, Issue 3, 2002. Oxford: Update Software.&lt;/p&gt;" NOTES_MODIFIED="2008-10-15 13:58:32 -0400" NOTES_MODIFIED_BY="[Empty name]" TYPE="COCHRANE_REVIEW">
<AU>Osborn DA, Evans N</AU>
<TI>Early volume expansion versus inotrope for prevention of morbidity and mortality in very preterm infants (Cochrane Review)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>3</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS MODIFIED="2008-10-15 13:58:32 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-15 13:58:32 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002056"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Osborn-2003" NAME="Osborn 2003" TYPE="JOURNAL_ARTICLE">
<AU>Osborn DA, Evans N, Kluckow M</AU>
<TI>Haemodynamic and antecedent risk factors of early and late periventricular/intraventricular hemorrhage in premature infants</TI>
<SO>Pediatrics</SO>
<YR>2003</YR>
<VL>112</VL>
<PG>33-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Padbury-1987" MODIFIED="2008-10-15 13:55:48 -0400" MODIFIED_BY="[Empty name]" NAME="Padbury 1987" TYPE="JOURNAL_ARTICLE">
<AU>Padbury JF, Agata Y, Baylen BG, Ludlow JK, Polk DH, Goldblatt E, Pescetti J</AU>
<TI>Dopamine pharmacokinetics in critically ill newborn infants</TI>
<SO>Journal of Pediatrics</SO>
<YR>1987</YR>
<VL>110</VL>
<PG>293-98</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Perkin-1982" MODIFIED="2008-10-15 13:55:57 -0400" MODIFIED_BY="[Empty name]" NAME="Perkin 1982" NOTES="&lt;p&gt;,,,,,,,,,,,,&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-10-15 13:55:57 -0400" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Perkin RM, Levin DL</AU>
<TI>Shock in the pediatric patient. Part II. Therapy</TI>
<SO>Journal of Pediatrics</SO>
<YR>1982</YR>
<VL>101</VL>
<PG>319-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Roze-1993" MODIFIED="2008-10-15 13:56:07 -0400" MODIFIED_BY="[Empty name]" NAME="Roze 1993" TYPE="JOURNAL_ARTICLE">
<AU>Roze JC, Tohier C, Maingueneau C, Lefevre M, Mouzard A</AU>
<TI>Response to dobutamine and dopamine in the hypotensive very preterm infant</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1993</YR>
<VL>69</VL>
<PG>59-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Seri-1995" NAME="Seri 1995" TYPE="JOURNAL_ARTICLE">
<AU>Seri I</AU>
<TI>Cardiovascular, renal and endocrine actions of dopamine in neonates and children</TI>
<SO>J Pediatr</SO>
<YR>1995</YR>
<VL>126</VL>
<PG>333-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Seri-1998a" MODIFIED="2008-10-15 13:56:18 -0400" MODIFIED_BY="[Empty name]" NAME="Seri 1998a" TYPE="JOURNAL_ARTICLE">
<AU>Seri I, Evans J</AU>
<TI>Addition of epinephrine to dopamine increases blood pressure and urine output in critically ill extremely low birth weight neonates with uncompensated shock</TI>
<SO>Pediatric Research</SO>
<YR>1998</YR>
<VL>43</VL>
<PG>194A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Seri-1998b" MODIFIED="2008-10-15 13:56:31 -0400" MODIFIED_BY="[Empty name]" NAME="Seri 1998b" TYPE="JOURNAL_ARTICLE">
<AU>Seri I, Abbasi S, Wood DC, Gerdes JS</AU>
<TI>Regional hemodynamic effects of dopamine in the sick preterm neonate</TI>
<SO>Journal of Pediatrics</SO>
<YR>1998</YR>
<VL>133</VL>
<PG>728-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Seri-2001" NAME="Seri 2001" TYPE="JOURNAL_ARTICLE">
<AU>Seri I</AU>
<TI>Circulatory support of the sick preterm infant</TI>
<SO>Semin Neonatol</SO>
<YR>2001</YR>
<VL>6</VL>
<PG>85-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Subhedar-2002" MODIFIED="2008-10-15 13:59:39 -0400" MODIFIED_BY="[Empty name]" NAME="Subhedar 2002" TYPE="COCHRANE_REVIEW">
<AU>Subhedar NV, Shaw NJ</AU>
<TI>Dopamine versus dobutamine for hypotensive preterm infants (Cochrane Review)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>3</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS MODIFIED="2008-10-15 13:59:39 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-15 13:59:39 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001242"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Venkataraman-1984" MODIFIED="2008-10-15 13:56:54 -0400" MODIFIED_BY="[Empty name]" NAME="Venkataraman 1984" TYPE="JOURNAL_ARTICLE">
<AU>Venkataraman PS, Babcock DS, Tsang RC, Ballard JL</AU>
<TI>Hepatic injury: a possible complication of dopamine infusion through an inappropriately placed umbilical vein catheter</TI>
<SO>American Journal of Perinatology</SO>
<YR>1984</YR>
<VL>1</VL>
<PG>351-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Versmold-1981" NAME="Versmold 1981" NOTES="&lt;p&gt;Versmold HT, Kitterman JA, Phibbs RH, Gregory GA. Tooley WH. Aortic blood pressure during the first 12 hours of life in infants with birth weight 610 to 4,220 grams. [Journal Article] Pediatrics. 67(5):607-13, 1981&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Versmold HT, Kitterman JA, Phibbs RH, Gregory GA. Tooley WH</AU>
<TI>Aortic blood pressure during the first 12 hours of life in infants with birth weight 610 to 4,220 grams</TI>
<SO>Pediatrics</SO>
<YR>1981</YR>
<VL>67</VL>
<PG>607-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Whitelaw-2002" MODIFIED="2008-10-15 13:57:01 -0400" MODIFIED_BY="[Empty name]" NAME="Whitelaw 2002" NOTES="&lt;p&gt;Whitelaw A, Ogbureke K, Subhedar N. Corticosteroids for hypotension in preterm infants (Protocol for a Cochrane Review). In: The &lt;br&gt;Cochrane Library, Issue 3, 2002. Oxford: Update Software.&lt;/p&gt;" NOTES_MODIFIED="2008-10-15 13:57:01 -0400" NOTES_MODIFIED_BY="[Empty name]" TYPE="COCHRANE_REVIEW">
<AU>Whitelaw A, Ogbureke K, Subhedar N</AU>
<TI>Corticosteroids for hypotension in preterm infants (Protocol for a Cochrane Review)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>3</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zaritsky-1984" MODIFIED="2008-10-15 13:57:16 -0400" MODIFIED_BY="[Empty name]" NAME="Zaritsky 1984" TYPE="JOURNAL_ARTICLE">
<AU>Zaritsky A, Chernow B</AU>
<TI>Use of catecholamines in pediatrics</TI>
<SO>Journal of Pediatrics</SO>
<YR>1984</YR>
<VL>105</VL>
<PG>341-50</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Phillipos-1996">
<CHAR_METHODS>
<P>Single centre trial, Canada. <BR/>Blinding of randomisation: unclear.<BR/>Blinding of intervention: yes, but method not reported. <BR/>Blinding of outcome assessment: yes, but method not reported. <BR/>Follow up: infants &gt;1750g: 2/20 (10%) not included in analysis. <BR/>Infants &lt;=1750g: 16 infants reported in abstract (?ongoing study). <BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Newborn infants &lt;24 hours age, hypotensive with mean BP 1SD below mean for weight and indwelling arterial line. Stratified into 3 groups of 20 infants: 750-1250g, 1251-1750g and &gt;1750g. <BR/>For infants &gt;1750g, n =20,<BR/>Dopamine group: n = 10, mean gestation 34 weeks, mean BW 2471g. <BR/>Adrenaline group: n = 10, mean gestation 36 weeks, mean BW 2642g. <BR/>Exclusions: congenital heart disease</P>
<P>
<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Dopamine titrated [5, 10, 15, 20 mcg/kg/min] every 20 minutes till desired mean BP achieved for 1 hour. <BR/>2. Adrenaline titrated [0.125, 0.25, 0.375, 0.5 mcg/kg/min] every 20 minutes till desired mean BP achieved for 1 hour.<BR/>If the desired BP was not achieved, the other drug was added.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Primary outcomes: effects on mean BP, mean pulmonary artery pressure, left and right ventricular cardiac indices and stroke volumes. <BR/>Outcomes: heart rate; invasive mean blood pressure; study endpoint was stable desired mean BP for 1 hour; echocardiographically measured left and right ventricular output, left and right stroke volume index, and mean pulmonary artery pressure. <BR/>No other clinical outcomes reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>The number of infants who received both inotropes or did not achieve primary end point not reported. <BR/>Highest infusion rate to obtain desired mean BP not reported. <BR/>Randomised, blinded study of dopamine vs adrenaline in hypotensive predominately preterm infants. <BR/>For infants &lt;=1750g: only 16 of the anticipated 40 infants were reported, possibly incomplete study. Authors contacted, awaiting reply.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR STUDY_ID="STD-Pellicer-2003">
<CHAR_STUDY_NAME>
<P>Randomised blinded controlled trial on the effects on brain haemodynamics of dopamine v epinephrine for inotropic support in preterm infants.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>Preterm infants &lt; 31 weeks GA or &lt; 1501 gram with systemic hypotension (MBP mmHg &lt; GA) within the first 24h of age</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Dopamine 2.5, 5, 7.5, 10 mcg/kg/min or epinephrine 0.125, 0.25, 0.375, 0.5 mcg/kg/min increasing every 20 minutes until a desired MAP is achieved and maintained. If this was not achieved the other drug was added.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Changes in cerebral blood volume, <BR/>cerebral oxyhaemoglobin and deoxyhaemoglobin<BR/>Mean arterial pressure<BR/>Heart rate<BR/>Transcutaneous pCO2<BR/>Peripheral oxygen saturations</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>May 2002</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Adelina Pellicer<BR/>apellicer.hulp@salud.madrid.org</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>Sample size required: 60<BR/>Currently 51 infants enrolled <BR/>
</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Phillipos-1996">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES"/>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>